Several once-famous trademarks lost protection to genericide: aspirin, escalator, thermos, zipper, cellophane, dry ice, and yo-yo. Each loss followed the same pattern — rapid category dominance, insufficient enforcement, and eventual consumer adoption of the brand name as the generic category term. The lessons apply to any brand dominating a new product category.
Study the historical genericide cases to identify the warning signs and prevention tactics that matter for your own brand.
The patterns that produced past genericide are predictable and avoidable; modern brands like Google and Kleenex avoided the same fate through deliberate intervention.
List the brand names customers use interchangeably with product categories in your industry — these are the genericide canaries.
Seven trademarks stand out as classic U.S. genericide cases, each from a different industry and era. Together they illustrate how genericide unfolds across diverse product categories.
| Former trademark | Industry | How it happened |
|---|---|---|
| Aspirin | Pharmaceutical | Bayer lost U.S. rights in 1921; no active enforcement post-WWI |
| Escalator | Building equipment | Otis used the term generically in its own catalogs |
| Thermos | Consumer goods | Generic usage won a 1963 federal court decision |
| Zipper | Apparel fasteners | B.F. Goodrich licensed too broadly in the 1930s |
| Cellophane | Packaging film | DuPont lost to genericide in 1936 |
| Dry ice | Refrigeration | Generic usage predated trademark enforcement |
| Yo-yo | Toys | Lost protection in 1960s federal court |
Each case involved a trademark owner who either failed to enforce, actively used the mark generically, or licensed too broadly. The pattern is not about market dominance alone — Kleenex and Xerox dominated their categories but retained protection. The difference was enforcement intensity and brand education strategy.[1]
Three patterns recur in historical genericide cases: pioneer category dominance, self-defeating usage by the trademark owner, and external adoption faster than enforcement could respond. Each pattern is observable in real time for brands facing genericide risk today.
Otis Elevator undermined its own escalator trademark by using the term descriptively in company catalogs (“Otis escalators” vs. the generic “moving stairway”). Bayer failed to enforce aspirin during the lean post-WWI years. DuPont lost cellophane in part because licensees used the term without proper source attribution. Each case involved a combination of the patterns rather than any single factor.
Several currently-protected trademarks exhibit warning signs of genericide drift. The brands still hold valid registrations, but consumer and media usage shows the early pattern that preceded historical genericide.
Each of these brands has active programs to prevent genericide. The programs cost meaningful sums — legal enforcement, marketing education, dictionary engagement — but the cost is far smaller than the value of the trademark asset being protected. For a small business growing into its category, studying how these brands manage genericide risk provides a practical playbook.
Bayer’s loss of aspirin in the United States is the canonical genericide case, and the specific tactical failures are well-documented. Bayer tried several standard genericide prevention approaches but executed them inconsistently during a period of weakened corporate control.
The Bayer case demonstrates that generic drift can become irreversible within a few years if enforcement lapses. It also shows that licensing without usage controls can accelerate rather than slow genericide. Modern brands like Xerox learned from these failures — Xerox licenses only with strict usage requirements and runs ongoing educational campaigns to prevent the drift that destroyed aspirin.[3]
The actionable lessons from historical genericide are consistent: use the trademark properly in all internal and external communications, enforce early and consistently against third-party generic use, educate customers and partners about proper usage, and treat genericide prevention as an ongoing operational function rather than a one-time legal matter.
Most small businesses will not face genericide risk in their first decade. The prevention habits are most valuable for brands that become dominant in their categories, and starting the habits early establishes patterns that scale with the brand. The cost of prevention is always smaller than the cost of recovery — and recovery, in the U.S. system, is often impossible once primary significance has shifted to the generic meaning.
Bayer lost aspirin. Otis lost escalator. DuPont lost cellophane. B.F. Goodrich lost zipper. Each company was a category-dominant leader with substantial resources. Each could have prevented the loss with better execution. None of them did.
Kimberly-Clark (Kleenex), Johnson & Johnson (Band-Aid), Xerox, 3M (Post-it), and Velcro face equivalent pressure today. Their marks are used generically in conversation, mentioned as verbs, substituted for competitor products in ordinary speech. But each of these brands has kept its trademark protection because they treated genericide as a serious threat and acted accordingly — with proper usage, relentless enforcement, and explicit consumer education.
The difference between the losers and the survivors is not market share, not famous status, not legal resources. The difference is whether the trademark owner understood that a trademark is a use-it-or-lose-it asset — and acted on that understanding every day across marketing, legal, and business operations.
This is where Responsible Asset-Building extends into long-term stewardship. A trademark registration is the beginning of trademark management, not the end. An educated consumer studies the historical losses to understand what the survivors did right — and builds the same disciplines into the brand from the start.
Yes, in multiple countries. Aspirin remains a protected Bayer trademark in Canada, Germany, France, Russia, and many other countries where Bayer successfully defended the mark after losing U.S. protection. The U.S. genericide decision in 1921 was jurisdiction-specific. Bayer has maintained aspirin as a trademark in most of the world where it operates.
The Ninth Circuit ruled in Elliott v. Google (2017) that verb use alone does not cause genericide — the primary significance test asks whether consumers' dominant understanding is as a source identifier or a category term. Google had maintained active enforcement, proper-adjective usage, and educational campaigns, and the court found that most consumers still associated 'Google' with the specific company even when using it as a verb.
Yes. In 2017, Velcro Companies released a video titled 'Don't Say Velcro' in which company lawyers sang about the need for consumers and media to call the product 'hook-and-loop fasteners' rather than 'velcro' generically. The campaign was a public acknowledgment of genericide pressure and a concrete educational effort to preserve the trademark. The video went viral and is studied as an example of brand-education tactics against genericide.
No official list exists, but legal scholars and trademark attorneys regularly identify candidates. Current high-risk marks include Kleenex, Band-Aid, Xerox, Google, Photoshop, Post-it, Velcro, Jacuzzi, Q-tips, and Rollerblade. Each of these brands actively defends its trademark through enforcement and consumer education. The specific risk level for each depends on the intensity of consumer generic usage and the trademark owner's response.
Almost never in U.S. law. Once genericide has been legally established, the term enters the public domain and cannot be re-registered by the former trademark owner. Bayer, Otis, DuPont, and B.F. Goodrich have all been unable to recover the specific generic terms they lost. The only path back would be abandoning the generic use entirely and re-establishing secondary meaning through decades of substantially exclusive use — a practically impossible task once the generic meaning is established.
Watch for your brand name being used as a verb or common noun in casual speech — especially by customers, media, or competitors. Early warning signs include informal verb use ('let me google that'), interchangeable use with competitor products ('hand me a Kleenex' for any tissue), and media articles using your brand name generically. Catching these signs early lets you intervene before the primary significance shifts.
Understand your brand, see what's worth protecting, and walk into any attorney conversation prepared. Enter your name and email once to unlock all three.